# EMA recommendation for Eli Lilly obesity medication

> Live situation record from CLSTR: https://clstr.news/situations/ema-recommendation-for-eli-lilly-obesity-medication
> Updated: 2026-10-19T00:53:52.000Z. Sources: 15. Developments: 2.

The European Medicines Agency (EMA) has issued a positive recommendation via its Committee for Medicinal Products for Human Use (CHMP) for Eli Lilly’s oral medication, Foundayo (orforglipron). The drug is a small-molecule GLP-1 receptor agonist designed to treat obesity and type 2 diabetes in adults.

Clinical studies involving approximately 4,740 to 4,840 participants demonstrated weight loss ranging from 5% to 11% depending on dosage. Reported side effects include gastrointestinal issues such as nausea, vomiting, and diarrhea. The medication is noted for its ease of administration as a once-daily tablet.

The recommendation now moves to the European Commission for a final decision, which is expected within approximately two months. Once authorized, individual EU member states will be responsible for negotiating pricing and reimbursement protocols.

## Timeline

### 2026-10-19: Eli Lilly's Foundayo receives positive EMA recommendation for obesity and diabetes

The EMA has recommended the approval of Eli Lilly’s oral medication Foundayo for treating obesity and type 2 diabetes in adults, marking a significant step toward its European market launch.

6 sources. https://clstr.news/cluster/eli-lillys-foundayo-receives-positive-ema-recommendation-for-obesity-and-diabetes

### 2026-10-16: Eli Lilly obesity pill receives EMA recommendation for approval

The EMA has recommended approval for Eli Lilly’s oral obesity and type 2 diabetes pill, orforglipron, paving the way for its potential release across the European Union.

9 sources. https://clstr.news/cluster/eli-lilly-obesity-pill-receives-ema-recommendation-for-approval

---
Cite as: EMA recommendation for Eli Lilly obesity medication. CLSTR, https://clstr.news/situations/ema-recommendation-for-eli-lilly-obesity-medication